 |
|
|
| |
Efficacy and Safety of Glecaprevir / Pibrentasvir in Patients Infected with HCV GT1 - 3 by Renal Impairment Status: A Pooled Analysis of Two Phase 3 Japanese Trials
|
| |
| |
Reported by Jules Levin
AASLD - the Liver Meeting 2017, 20 - 24 October 2017, Washington, DC
Masanori Atsukawa1, Kazuaki Chayama2, Fumitaka Suzuki3, Ken Sato4, Yoshiyasu Karino5, Tomofumi Atarashi6, Yoshiiku Kawakami2, Atsushi Naganuma7, David Pugatch8, Katia Alves8, Koji Kato8, Rebecca Redman8, Margaret Burroughs8, Manal Abunimeh8, Wangang Xie8, Hiromitsu Kumada31Nippon Medical School Chiba Hokusoh Hospital, Chiba, Japan; 2Hiroshima University Hospital, Hiroshima, Japan; 3Toranomon Hospital, Tokyo, Japan; 4Gunma University Hospital, Maebashi, Japan; 5JA Hokkaido P.W.F.A.C Sapporo-Kosei General Hospital, Sapporo, Japan; 6JA Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Japan; 7NHO Takasaki General Medical Center, Takasaki, Japan; 8AbbVie, Inc., North Chicago, IL
|
| |
|
|
|
|
|
